Advanced Blood Biomarkers: ApoB, Lp(a), Homocysteine, TMAO, Ferritin

LDL Cholesterol Misses the Particle That Causes the Damage

Standard lipid panels measure LDL cholesterol (LDL-C) — the total amount of cholesterol carried inside LDL particles. What they do not measure is the number of LDL particles (LDL-P) or the number of apolipoprotein B-100 (ApoB) molecules — one per each atherogenic lipoprotein particle. The problem: particle number predicts cardiovascular events better than cholesterol content in large epidemiological studies. Two people can have identical LDL-C of 130 mg/dL but dramatically different particle counts depending on particle size. The person with more numerous small, dense LDL particles carries a much higher atherosclerotic risk than the person with fewer large, buoyant LDL particles — yet their standard lipid panel looks identical.

ApoB vs. LDL-P: The Better Predictor

Apolipoprotein B-100 (ApoB) is the structural protein on every atherogenic lipoprotein particle: LDL, VLDL, IDL, and Lp(a). One molecule of ApoB is present on each particle, making ApoB measurement equivalent to a direct count of all atherogenic particles simultaneously — something LDL-P does not capture. ApoB testing is widely available, standardized across laboratories, and not significantly more expensive than a standard lipid panel.

A 2021 analysis of the AMORIS cohort (500,000+ individuals) found ApoB consistently outperformed LDL-C and non-HDL-C for predicting myocardial infarction across all subgroups, including those with high triglycerides (where LDL-C calculation using Friedewald equation becomes least reliable).

Lipoprotein(a): The Genetic Cardiovascular Risk Factor

Lipoprotein(a) — Lp(a) — is a modified LDL particle with an additional apolipoprotein(a) protein attached via a disulfide bond. Unlike LDL-C, Lp(a) levels are 80–90% determined by genetics (specifically the LPA gene on chromosome 6q). Diet, exercise, and standard lipid-lowering therapies have minimal effect on Lp(a). Elevated Lp(a) (>50 mg/dL, or >125 nmol/L) is the single most common genetic cardiovascular risk factor, affecting approximately 20% of the global population. It independently predicts myocardial infarction, aortic stenosis, and peripheral arterial disease. Measurement should be done once in a lifetime for genetic risk assessment; results do not change significantly over time. RNA-based therapeutics including pelacarsen (Novartis) and olpasiran (Amgen) are in phase 3 trials specifically targeting elevated Lp(a).

Homocysteine: Vascular Toxin, B Vitamin Dependency

Homocysteine is a sulfur-containing amino acid produced during methionine metabolism. Elevated plasma homocysteine (>15 μmol/L, and particularly >20 μmol/L) damages endothelial cells, promotes oxidative stress, and is associated with cardiovascular disease, stroke, and dementia. The cause of elevated homocysteine in most people is inadequate dietary B12, B6, or folate — the vitamins required to remethylate homocysteine back to methionine (via folate/B12) or transsulfurate it to cysteine (via B6). MTHFR gene variants, particularly C677T homozygosity (present in ~10% of populations), reduce the efficiency of this remethylation and can raise homocysteine independent of dietary intake. B vitamin supplementation reliably lowers homocysteine — but randomized trials of B vitamin supplementation have not consistently reduced cardiovascular events, suggesting elevated homocysteine may be a marker rather than a direct cause.

• Optimal homocysteine is generally considered below 9–10 μmol/L, with the upper reference limit at approximately 15 μmol/L.
• Vegans and strict vegetarians frequently have elevated homocysteine due to B12 deficiency — a direct metabolic consequence of removing the primary dietary B12 source.
• Methylfolate (5-MTHF) supplementation is preferred over folic acid for people with MTHFR variants, as these individuals cannot efficiently convert folic acid to active methylfolate.

TMAO: Gut Bacteria and Cardiovascular Risk

Trimethylamine N-oxide (TMAO) is produced when gut bacteria metabolize dietary choline, phosphatidylcholine, and L-carnitine — found in red meat, eggs, and fish. The bacteria produce trimethylamine (TMA); the liver oxidizes TMA to TMAO via FMO3 enzyme. A landmark 2013 study by Stanley Hazen's group at the Cleveland Clinic (Nature Medicine) found plasma TMAO levels predicted cardiovascular events in 4,007 patients independently of traditional risk factors. Subsequent meta-analyses have confirmed this association. However, the causality question remains open: TMAO may be a marker of a gut microbiome composition that promotes cardiovascular disease rather than a direct cause. Fish consumption also raises TMAO but is epidemiologically associated with cardiovascular protection — a paradox not yet fully resolved.

Ferritin: Energy, Iron Stores, and the Optimal Range Debate

Ferritin is the primary intracellular iron storage protein; serum ferritin is a proxy for body iron stores. The standard laboratory reference range is wide: 12–300 ng/mL for men, 12–150 ng/mL for women. Within this "normal" range, significant functional differences exist. Ferritin below 30 ng/mL associates with iron deficiency symptoms (fatigue, cold intolerance, hair loss) even without frank anemia. Ferritin above 150–200 ng/mL in the absence of inflammation may reflect iron overload, associated with increased oxidative stress, liver damage, and in hereditary hemochromatosis, organ failure. Ferritin is also an acute-phase reactant — it rises during infection and inflammation, masking true iron deficiency in chronically inflamed individuals. The optimal range debate centers on a "sweet spot" (approximately 50–100 ng/mL for most adults), though this is not yet formalized in clinical guidelines.

This article is for informational purposes only. Consult a qualified healthcare professional.